Literature DB >> 35140532

Differential Association Between Significant Coronary Stenosis and Cardiac Troponin T Serial Algorithms in Chronic Kidney Disease Patients Diagnosed with Non-ST-Segment Elevation Acute Coronary Syndromes.

Thanat Tangpaisarn1, Nirut Srimakam1, Vichai Senthong2, Pariwat Phungoen1, Praew Kotruchin1.   

Abstract

BACKGROUND: High-sensitivity cardiac troponin T (hs-cTnT) is recommended for diagnosing non-ST segment elevation acute coronary syndromes (NSTE-ACS). While the guidelines recommend using the 0,1-hour (hr) and 0,3-hr hs-cTnT algorithms, their efficacy has not been clearly established in chronic kidney disease (CKD) patients. We aimed to assess the differential associations between the two algorithms mentioned above with significant coronary stenosis in CKD patients.
METHODS: This was a retrospective cohort study. Patients aged ≥18 years who were diagnosed with NSTE-ACS and had undergone coronary angiogram were recruited. The differential association between significant coronary stenosis and being ruled in based on the 0,1-hr and 0,3-hr hs-cTnT algorithm was analyzed and reported.
RESULTS: There were 158 and 160 patients in the CKD and normal renal function groups. Among CKD patients, determinants of significant coronary stenosis were hypertension (OR = 2.68; 95% CI 1.10-6.50) and being ruled in by the 0,3-hr algorithm (OR = 3.65; 95% CI 1.27-10.52). In the normal renal function group, age (OR = 1.04; 95% CI 1.01-1.06), male sex (OR = 2.15; 95% CI 1.09-4.22), and being ruled in by the 0,1-hr algorithm (OR = 3.12; 95% CI 1.20-8.10) were associated with significant coronary stenosis.
CONCLUSION: Being ruled in according to the 0,3-hr algorithm was significantly associated with coronary stenosis in CKD patients, making this a likely algorithm of choice in these patients.
© 2022 Tangpaisarn et al.

Entities:  

Keywords:  Asian; acute coronary syndromes; cardiac biomarkers; renal dysfunction; troponin

Year:  2022        PMID: 35140532      PMCID: PMC8818962          DOI: 10.2147/OAEM.S348378

Source DB:  PubMed          Journal:  Open Access Emerg Med        ISSN: 1179-1500


Introduction

Coronary artery disease (CAD) is a leading cause of death worldwide.1 There are several known atherosclerotic risk factors for CAD, both reversible and irreversible.2 One significant risk factor is renal dysfunction.3,4 Patients who have an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 or chronic kidney disease (CKD)5 are at risk of cardiovascular disease, partly due to preexisting cardiovascular risk factors (eg, hypertension and dyslipidemia).3,6–8 Other novel cardiovascular risk factors in CKD patients are chronic inflammation, calcium–phosphate metabolism disturbances, oxidative stress, malnutrition, anemia, fluid overload, fluctuation in systemic fluid volume, disturbances in the coagulation system, accumulation of metabolic products, and numerous undefined toxic agents associated with atherosclerosis.9–11 Unfortunately, the diagnosis of CAD in CKD patients often requires thorough history taking and physical examination as well as a high level of suspicion due to their atypical presentations.12 Generally, an electrocardiogram (ECG) is performed in patients who present at the emergency department (ED) with symptoms compatible with acute coronary syndromes (ACS). If the ECG does not show ST-segment elevation myocardial infarction (STEMI), high-sensitivity cardiac troponin (hs-cTn) is recommended as a cardiac biomarker for evaluating whether patients have non-ST segment elevation acute coronary syndromes (NSTE-ACS).13 CKD is one of the determinants of cardiac troponin (cTn) level.14 There is evidence of chronic cTn elevation in CKD patients, even in the absence of significant coronary artery stenosis.15 There have also been studies aimed at determining the cTn cut-off level for diagnosing myocardial infarction in CKD patients.16–18 However, serial testing has yielded the best results in the screening for and diagnosing of NSTE-ACS in both CKD patients and those with normal renal function.19–23 Previous treatment guidelines recommended using a 0,3-hour algorithm in the serial testing of cTn, and this method has since been adopted worldwide.24 However, due to the development of hs-cTn assays, the latest European Society of Cardiology (ESC) guidelines for the management of ACS in patients presenting without persistent ST-segment elevation recommend the use of a 0,1-hour algorithm regardless of renal function to rule in and rule out NSTE-ACS at the ED rapidly.13 Many studies, however, have shown the efficacy of the 0,1-hour algorithm to be lower than that of the 0,3-hour algorithm in CKD patients.19,23 Furthermore, in current real-world practice, it is not uncommon for ED physicians to use the 0,3-hour algorithm to test for NSTE-ACS regardless of the recommendations.22,23 We, therefore, aimed to assess the differential association between these two algorithms and significant coronary stenosis in CKD patients.

Materials and Methods

Study Design and Population

This was a retrospective cohort study conducted in the ED of Srinagarind hospital, a 1000-bed tertiary care university hospital in northeast Thailand, from December 2014 to December 2018. Patients aged 18 years (yr) or over who presented with chest pain were initially diagnosed with NSTE-ACS and underwent coronary angiogram (CAG) during the same admission were recruited. Patients who presented with cardiac arrest or had incomplete data regarding serum creatinine levels, CAG, or hs-cTnT were excluded from the study. This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The Khon Kaen University Ethics Committee for Human Research approved the study and waived the written individual informed consent as the research is no more than minimal risk. To protect confidentiality, all identifiers were eliminated from the obtained data (HE621312).

Operating Definitions

NSTE-ACS

NSTE-ACS, including unstable angina and non-ST-elevation myocardial infarction (NSTEMI), was diagnosed by an intervention cardiologist on duty according to the 4th universal definition of myocardial infarction criteria (details are provided in the ).25

CKD

CKD was defined as an eGFR of less than 60 mL/min/1.73 m2 computed according to the KDICO formula (details are provided in the ).26

0,1-hr Algorithm

NSTE-ACS was ruled in according to the 0,1-hr algorithm if hs-cTnT was ≥52 ng/l at presentation or if the difference between hs-cTnT at presentation and after 1 hour was ≥5 ng/l (Figure 1) in accordance with the latest ESC guidelines.13
Figure 1

0,1-hr rule-in algorithms using hs-cTnT assays (Elecsys®) in patients presenting with suspected non-ST-elevation acute coronary syndromes.

0,1-hr rule-in algorithms using hs-cTnT assays (Elecsys®) in patients presenting with suspected non-ST-elevation acute coronary syndromes.

0,3-hr Algorithm

NSTE-ACS was ruled in according to the 0,3-hr algorithm if hs-cTnT was ≥70 ng/l at presentation, if there was a >20% difference in hs-cTnT at presentation and after 3 hours, if hs-cTnT at presentation was ≥14 ng/l, or if there was a >7 ng/l change in hs-cTnT after 3 hours, if hs-cTnT at presentation was <14 ng/l (Figure 2), according to the 2015 ESC guidelines.24
Figure 2

0,3-hr rule-in algorithm of non-ST-elevation acute coronary syndromes using high-sensitivity cardiac troponin assays (Elecsys®).

0,3-hr rule-in algorithm of non-ST-elevation acute coronary syndromes using high-sensitivity cardiac troponin assays (Elecsys®).

Positive CAG

Positive CAG was defined as >50% stenosis of the left main coronary artery or >70% stenosis of right coronary artery (RCA), left circumflex coronary artery (LCx), or left anterior descending (LAD) coronary artery.27

Primary Outcome and Statistical Analysis

The primary outcome was the association between significant coronary stenosis and NSTE-ACS being ruled in based on the two hs-cTnT algorithms (0,1-hr and 0,3-hr) in both CKD patients and those with normal renal function. The secondary outcomes were other determinants of significant coronary stenosis. The patient’s baseline characteristics and clinical measurements were reported as mean ± standard deviation (SD) for continuous variables and number and percentage for categorical variables. For comparison between the CKD and the normal renal function groups, an independent sample t-test was used for continuous variables and Pearson’s chi-square test for proportions for categorical variables. We used the cross tables derived from the official ESC assay-specific cut-off criteria for rule-in to determine the rule-in group.13,24 The association between significant coronary stenosis and rule-in status as a categorical variable (1 = ruled in, 0 = not ruled in) together with other conventional cardiovascular risk factors were subjected to binary logistic regression analysis and presented as unadjusted odd ratios (OR). Considering clinical importance and using P < 0.20 as a criterion, age, sex (male), and hypertension (HT) were included in the regression analysis, with the rule-in group from the 0,1-hr algorithm in model 1 and the 0,3-hr algorithm in model 2. The adjusted ORs were also reported. All hypothesis testing was 2-tailed, and P < 0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS statistics for MAC, version 23.0 (SPSS Inc).

Results

Patient Characteristics

We enrolled 318 patients in this study, 158 in the CKD group and 160 in the normal renal function group. Baseline characteristics of patients with CKD differed from those with normal renal function in multiple respects, including older age (70 yr vs 62 yr, P < 0.001) and higher prevalence of HT and diabetes mellitus (DM; 83.0% vs 54.7% and 63.3% vs 26.7%, respectively; P < 0001). More patients in the CKD group were ruled in by both the 0,1-hr and the 0,3-hr algorithm (Table 1).
Table 1

Baseline Characteristics of the NSTE-ACS Patients, Categorized by Kidney Function

All Patients (N=318)Patients with CKD (n=158)Patients without CKD (n=160)P
Age, years66.3±13.170.3±10.462.4±14.2<0.001
Male, n (%)182 (57.2)85 (53.8)97 (60.6)0.257
Chest pain onset, hr455±1084569±1310343.5±7910.074
Duration of chest pain, hr3.68±15.173.52±18.513.84±11.020.858
Initial vital signs:
SBP, mmHg136±31139±32133±290.089
DBP, mmHg72±1771±1674±190.097
PR, bpm83±2082±1984±210.316
O2 sat, %95±1396±694±170.116
Laboratory results:
eGFR58.3±35.128.3±19.288.0±17.8<0.001
NT-proBNP, pg/mL1750.0±8057.62730.5±11,054.9781.9±2621.10.031
Initial hs-cTnT, ng/dL413.92±1277.80376.69±830.26450.68±1603.700.606
1-hr, ng/dL371.79±1131.12238.59±304.51479.04±1490.850.214
3-hr, ng/dL479.61±1318.15560.02±1359.32387.00±1271.370.395
1-hr algorithm, n (%)200 (85.1)124 (93.9)76 (73.8)<0.001
3-hr algorithm191 (78)115 (85.8)76 (68.5)0.002
Hypertension, n (%)204 (68.7)122 (83.0)82 (54.7)<0.001
Diabetes mellitus, n (%)133 (44.8)93 (63.3)40 (26.7)<0.001
Ejection fraction, %37.9±24.939.9±23.535.9±26.20.162
LV mass index132.6±53.5130.9±52.3133.9±55.60.865
Positive CAG results, n (%)185 (64)100 (70.4)85 (57.8)0.028
  - SVD, n (%)69 (23.9)31 (21.8)38 (25.9)0.491
  - DVD, n (%)45 (15.6)25 (17.6)20 (13.6)0.418
  - TVD, n (%)68 (23.5)42 (29.6)26 (17.7)0.019
  - LM disease, n (%)32 (11.1)21 (14.8)11 (7.5)0.060
PCI/CABG performed, n (%)154 (53.1)82 (57.3)72 (49)0.160
LOS, day13±1616±1711±160.007
Dead, n (%)17 (6.3)11 (8)6 (4.5)0.317

Abbreviations: NSTE-ACS, non-ST segment elevation acute coronary syndromes; hr, hour; SBP, systolic blood pressure; DBP, diastolic blood pressure; mmHg, millimeter of mercury; PR, pulse rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-cTnT, high-sensitivity cardiac troponin T; CAG, Coronary Angiogram; SVD, single vessel disease; DVD, double vessel disease; TVD, tripple vessel disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LOS, length of stay.

Baseline Characteristics of the NSTE-ACS Patients, Categorized by Kidney Function Abbreviations: NSTE-ACS, non-ST segment elevation acute coronary syndromes; hr, hour; SBP, systolic blood pressure; DBP, diastolic blood pressure; mmHg, millimeter of mercury; PR, pulse rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-cTnT, high-sensitivity cardiac troponin T; CAG, Coronary Angiogram; SVD, single vessel disease; DVD, double vessel disease; TVD, tripple vessel disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LOS, length of stay. There was a higher prevalence of significant coronary stenosis in the CKD group than in the normal renal function group (70.4% vs 57.8%, P = 0.028). Furthermore, length of stay (LOS) was longer in the former group than in the latter (16 days vs 11 days, P = 0.007; Table 1).

Determinants of a Significant Coronary Stenosis

Factors associated with significant coronary stenosis in the total study population were an older age (OR = 1.04; 95% CI 1.02–1.06), male sex (OR = 1.82; 95% CI 1.12–2.95), HT (OR = 1.93; 95% CI 1.16–3.22), and NSTE-ACS being ruled in by the 0,1-hr algorithm (OR = 3.53; 95% CI 1.61–7.73) or 0,3-hr algorithm (OR 2.24; 95% CI = 1.16–4.34; Table 2).
Table 2

Unadjusted Odd Ratio (OR) of a Significant Coronary Stenosis by Using Regression Analysis in the Total Population and After Categorized by Kidney Function

CovariatesTotal Population (N=318)CKD (n=158)Non-CKD (n=160)
OR (95% CI)P-valueOR (95% CI)P-valueOR (95% CI)P-value
Age, per 1 year1.04 (1.02–1.06)<0.0011.03 (1.00–1.07)0.0801.04 (1.01–1.06)0.008
Sex, (Men=1, Women =0)1.82 (1.12–2.95)0.0161.67 (0.81–3.46)0.1652.15 (1.09–4.22)0.027
Creatinine, per 1 mg/dL1.08 (0.98–1.19)0.1031.03 (0.93–1.15)0.5501.76 (0.36–8.51)0.485
Hypertension, (1=Yes, 0=No)1.93 (1.16–3.22)0.0122.68 (1.10–6.50)0.0301.34 (0.69–2.59)0.385
Ejection fraction, per 1%1.01 (1.00–1.02)0.2761.01 (1.00–1.03)0.1631.00 (0.99–1.01)0.919
Rule in 0,1 hr3.53 (1.61–7.73)0.0023.72 (0.79–17.65)0.0983.12 (1.20–8.10)0.020
Rule in 0,3 hr2.24 (1.16–4.34)0.0173.65 (1.27–10.52)0.0161.34 (0.56–3.18)0.510

Abbreviation: hr, hour.

Unadjusted Odd Ratio (OR) of a Significant Coronary Stenosis by Using Regression Analysis in the Total Population and After Categorized by Kidney Function Abbreviation: hr, hour. Among CKD patients, factors associated with significant coronary stenosis were HT (OR = 2.68; 95% CI 1.10–6.50), and NSTE-ACS being ruled in based on the 0,3-hr algorithm (OR = 3.65; 95% CI 1.27–10.52; Table 2). In the normal renal function group, factors associated with significant coronary stenosis were older age (OR = 1.04; 95% CI 1.01–1.06), male sex (OR = 2.15; 95% CI 1.09–4.22), and NSTE-ACS being ruled in by the 0,1-hr algorithm (OR = 3.12; 95% CI 1.20–8.10). After adjusting for age, male sex, and HT, patients in the total population ruled in by either the 0,1-hr algorithm or 0,3-hr algorithm were significantly more likely to have significant coronary stenosis (OR = 3.09; 95% CI 1.37–6.94 and OR = 2.60; 95% CI 1.27–5.34, respectively; Table 3). However, NSTE-ACS being ruled in by the 0,3-hr algorithm was the only independent determinant of significant coronary stenosis in the CKD patients. In patients with normal renal function, older age, male sex, and NSTE-ACS being ruled in by the 0,1-hr algorithm were significantly associated with significant coronary stenosis, but being ruled in by the 0,3-hr algorithm was not (Table 3).
Table 3

Adjusted Odd Ratio (OR) of a Significant Coronary Stenosis by Using Regression Analysis

CovariatesTotal Population(N=318)CKD(n=158)Non-CKD(n=160)
OR (95% CI)P-valueOR (95% CI)P-valueOR (95% CI)P-value
Model 1
Age, per 1 year1.03(1.01–1.06)0.0251.02(0.98–1.06)0.4281.04(1.01–1.08)0.034
Sex, (Men=1, Women =0)2.34(1.24–4.43)0.0091.34(0.57–3.15)0.4964.80(1.74–13.27)0.003
Hypertension, (1=Yes, 0=No)1.59(0.80–3.16)0.1851.55(0.52–4.64)0.4311.94(0.70–5.42)0.205
Rule in 0,1 hr3.09(1.37–6.94)0.0063.00(0.60–15.00)0.1813.69(1.29–10.56)0.015
Model 2
Age, per 1 year1.04(1.02–1.07)0.0011.02(0.98–1.06)0.4531.06(1.02–1.10)0.001
Sex, (Men=1, Women =0)3.27(1.73–6.18)<0.0011.85(0.77–4.40)0.1656.25(2.28–17.14)<0.001
Hypertension, (1=Yes, 0=No)1.38(0.71–2.71)0.3451.97(0.64–6.01)0.2360.95(0.38–2.37)0.917
Rule in 0,3 hr2.60(1.27–5.34)0.0093.17(1.06–9.52)0.0402.39(0.87–6.60)0.092

Abbreviation: hr, hour.

Adjusted Odd Ratio (OR) of a Significant Coronary Stenosis by Using Regression Analysis Abbreviation: hr, hour.

Discussion

This study showed that being ruled in by either the 0,1-hr algorithm or the 0,3-hr algorithm was significantly associated with significant coronary stenosis in patients with suspected NSTE-ACS. However, there was a differential association between the rule-in group determined by each algorithm in CKD patients. CKD patients ruled in based on the 0,3-hr algorithm but not the 0,1-hr algorithm were more likely to have significant coronary stenosis. In a 2018 study by Twerenbold et al,19 the 0,1-hr algorithm yielded a lower specificity and overall efficacy in CKD patients than those with normal renal function (96.5% vs 88.7% and 81% vs 51%, respectively). Furthermore, Chesnaye et al found that CKD patients had chronically elevated cTn.15 In addition, Sittichanbuncha et al, Chenevier-Gobeaux et al, and Van Lente et al found a higher cTn cut-off point to be more effective in CKD patients.16–18 Studies by Eggers et al and Chesnaye et al found that cTn was elevated in conditions other than type 1 myocardial infarction (MI) such as tachycardia, heart failure, and hypertensive crisis.14,15 The two algorithms’ differential association with significant coronary stenosis in this study may be explained by the false or chronic elevation of hs-cTnT in CKD patients. The initial hs-cTnT cut-off level for the 0,1-hr algorithm is 52 ng/L, much lower than that of the 0,3-hr algorithm (70 ng/L). The lower cut-off level of the 0,1-hr algorithm might result in patients being recruited whose hs-cTnT elevation is caused by diseases or conditions other than type 1 MI. Our study showed that the determinants of significant coronary stenosis patients with normal renal function were older age and male sex, generally considered conventional risk factors for CAD.2 Another factor significantly associated with significant coronary stenosis was NSTE-ACS being ruled in based on the 0,1-hr algorithm, which has proven its efficacy and is recommended for use in the latest ESC guidelines.13 However, we found that being ruled in based on the 0,3-hr algorithm was not associated with significant coronary stenosis. A possible explanation might be that a 3-hour interval for serial hs-cTnT measurement allows for its elevation by conditions associated with cardiac myocyte injury other than acute type 1 MI. This hypothesis is supported by some previous studies, which have attributed cTn release to tachycardia, pericarditis, congestive heart failure, myocarditis, Takotsubo syndrome, pulmonary embolus, hypertrophic cardiomyopathy, and severe aortic stenosis.28,29 Furthermore, we explored the final diagnoses in patients with a normal renal function whose coronary angiograms did not reveal significant lesions. These patients were diagnosed with vasospasm (17%), arrhythmias (13%), myocarditis (13%), heart failure (13%), sepsis (13%), hypertrophic cardiomyopathy (6%), stroke (6%), Takotsubo syndrome (6%), and endocarditis (3%). To the best of our knowledge, this was the first study to examine the association between significant coronary stenosis and the hs-cTnT algorithm used. All coronary angiograms were performed in the same tertiary care center. The same hs-cTnT assay (Elecsys®) was used for both the 0,1-hr and 0,3-hr algorithm, which allowed for clear data, unbiased comparison. However, there were some potential limitations to this study. First, due to the retrospective nature of the data collection, some laboratory data and some risk factors that might influence the results were missing. Second, although interventional cardiologists determined coronary angiogram results, we did not collect the data regarding any additional angiogram methods used such as intravascular ultrasound (IVUS) or fractional flow reserve (FFR). Third, this was a single-center study conducted at a university hospital in rural Thailand, apart from the relatively small sample size which may have some effect on the power of the study, our study population may differ from others in terms of biological, genetic, and cultural factors. Care should thus be taken when extrapolating the results.

Conclusions

Patients ruled in using the 0,3-hr algorithm were significantly more likely to have significant coronary stenosis, making this algorithm a possible algorithm of choice in CKD patients. However, a randomized clinical trial might be needed to determine the clinical efficacy of this algorithm in predicting coronary angiogram results in CKD patients.
  28 in total

1.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

Authors:  A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

2.  Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey.

Authors:  Chi-Yuan Hsu; Charles E McCulloch; Gary C Curhan
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

3.  Fourth Universal Definition of Myocardial Infarction (2018).

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Bernard R Chaitman; Jeroen J Bax; David A Morrow; Harvey D White
Journal:  Circulation       Date:  2018-11-13       Impact factor: 29.690

4.  Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation.

Authors:  Pim A L Tonino; William F Fearon; Bernard De Bruyne; Keith G Oldroyd; Massoud A Leesar; Peter N Ver Lee; Philip A Maccarthy; Marcel Van't Veer; Nico H J Pijls
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

5.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

6.  The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease.

Authors:  Paul Muntner; L Lee Hamm; John W Kusek; Jing Chen; Paul K Whelton; Jiang He
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

7.  Renal Dysfunction Influences the Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin I.

Authors:  Ian Gunsolus; Yader Sandoval; Stephen W Smith; Anne Sexter; Karen Schulz; Charles A Herzog; Fred S Apple
Journal:  J Am Soc Nephrol       Date:  2017-10-27       Impact factor: 10.121

8.  Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate.

Authors:  Jolanta Malyszko; Hanna Bachorzewska-Gajewska; Jacek Malyszko; Nomy Iaina-Levin; Grazyna Kobus; Slawomir Dobrzycki
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

9.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

10.  Cardiac Troponins for the Diagnosis of Acute Myocardial Infarction in Chronic Kidney Disease.

Authors:  Daniel Kraus; Beatrice von Jeinsen; Stergios Tzikas; Lars Palapies; Tanja Zeller; Christoph Bickel; Georg Fette; Karl J Lackner; Christiane Drechsler; Johannes T Neumann; Stephan Baldus; Stefan Blankenberg; Thomas Münzel; Christoph Wanner; Andreas M Zeiher; Till Keller
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.